each dNTP and 3.5 U of AmpliTaq (Applied Biosytems). For b-globin amplification, the thermocycler was set using a hold cycle of 94ЊC for 10 min, followed by 40 cycles of 1 min at 94ЊC, 1 min at 65ЊC, and 1 min at 72ЊC. The last extension step was continued for 10 min. b-globin amplicons were detected by gel electrophoresis.
To date, we have examined specimens from 57 patients. Sixteen were excluded from consideration in our study because they tested PCR-negative for b-globin DNA, indicating either an inadequate amount of DNA or the presence of PCR inhibitors. We detected mtrII DNA of CMV in 6 (14.6%) of 41 patients. Three patients were positive by both gel electrophoresis and spectrophotometric analysis, whereas 3 were positive by spectrophotometry only. No additional positive specimens were detected using gel electrophoresis plus a chemiluminescent Southern blot. Four patients known not to have CAD all tested negative for CMV. Of the 37 patients for whom a diagnosis of CAD was confirmed, 6 (16%) tested positive for CMV. The average age of the CMV-positive group was 61 years and of the CMV-negative group with known CAD, 69 years. Half (3/ 6) of the CMV-positive group and 58% of the CMV-negative group were white; all of the CMV-positive patients were male.
Our incidence of 16% CMV positivity for patients undergoing surgery for cardiovascular disease falls far below the incidence of 90% reported on a cohort of surgical specimens from patients with atherosclerotic disease by researchers at Baylor College of Medicine. Using the same primer sequences to detect the mtrII region by PCR, Melnick et al. [2] found CMV in 90% of atherosclerotic plaque tissues and uninvolved aortic biopsies collected from 60 patients undergoing vascular surgery. In that study, amplification of the late gene region resulted in only 76% positivity, and an immediate-early primer pair amplified none of the mtrII-positive specimens.
We chose to use the mtrII primers in our study in order to closely adhere to the protocol of the Baylor study. As stated, our positivity rate of 16% falls far below that of the Houston study (90% positivity). However, our data are similar to the reported incidence of CMV DNA in coronary arteries collected from autopsy at the Mayo Clinic [3] , in which 21 coronary artery specimens obtained from 11 (22%) of 49 cases tested positive for CMV DNA using two separate pairs of CMV primers, with detection by gel electrophoresis and confirmation by Southern blot. In that latter study [3] , no obvious correlation with the presence of CMV and the degree of atherosclerosis was found. It could be argued that the chemiluminescent detection system that we used is less sensitive than the radioactive probe assay used by Melnick et al. in the Houston study [2] ; however, inasmuch as we used the same primers and probe sequences, we do not believe that this can explain the large discrepancy in the data (16% vs. 90%).
In summary, we have molecular findings to support the se- 
Pentoxifylline in Human Immunodeficiency VirusPositive Tuberculosis: Safety at 4 Years
To the Editor-Two years ago, we reported in this Journal a randomized clinical trial of the tumor necrosis factor-a (TNFa) inhibitor, pentoxifylline, as adjunctive therapy in human immunodeficiency virus type 1 (HIV-1)-infected persons with pulmonary tuberculosis (TB) [1] . The study found that pentoxifylline therapy resulted in decreased plasma HIV-1 RNA and b 2 -microglobulin and, in a subset of moderately anemic subjects, improved blood hemoglobin. At the time the study was planned, concern was raised that, given the role of TNFa in immune defenses against Mycobacterium tuberculosis, inhibition of TNF-a might lead to increased rates of treatment failure or relapse. The report, reflecting 1.5 years of follow-up, did not completely resolve this question, as it noted trends toward increased adverse outcomes in TB therapy in the pentoxifylline arm (7 vs. 2 controls) that did not reach statistical significance.
We recently completed a second analysis of outcomes in this cohort, after nearly 4 years of follow-up. Of the original study subjects, 91% could be included in this analysis; the rest were lost to follow-up. As expected, the number of adverse events has increased significantly with time. However, the trend toward increased adverse events in the pentoxifylline arm has not continued. As indicated in table 1 above, TB adverse events and total deaths do not differ in the two treatment arms. The sample size is sufficient to identify with 80% certainty a 2.8-fold increase in the rate of TB adverse events-less than that observed in the original report.
This represents the longest period of observation of HIV-1-infected subjects with active opportunistic infections treated with a TNF-a inhibitor. It indicates that such treatment does not increase the risks of relapse, other opportunistic infections, or death. However, the extent of the reduction in TNF-a observed with pentoxifylline is modest, as is that for plasma HIV RNA. It is therefore appropriate that future studies of other, more highly active TNF-a inhibitors should similarly evaluate both short-and long-term safety with respect to potential infectious complications of such therapy.
